Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Assistance Publique - Hôpitaux de Paris | OTHER |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to determine whether pro-adrenomedullin (Mr proADM)in addition to clinical evaluation is effective to predict outcome of acute exacerbations of COPD patients visiting the emergency room(ER).
Acute exacerbation of COPD (AECOPD)are usual and frequent cause of admission in emergency room (ER). No validated clinical or biological predictor of evolution are available.
The main objective is to determine the prognosis value of Mr proADM in addition to the clinical risk stratification for AE COPD patients in ER.
Patients presenting with a AECOPD diagnosis in ER will have a blood sample collected and freezed at their admission. Mr proADM will be assessed at the end of the study. Clinicians in charge of patients will not have the result during the management of their patients. This study implies no change in the patients' management.
Data related to the patients'demographic,current exacerbation and basic COPD characteristics will be collected.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| AECOPD Mr proADM | No Intervention | Patients involved in this study will have a simple blood sample collected for Mr proADM assessment at the end of study |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| AECOPD Mr proADM | Other |
|
| Measure | Description | Time Frame |
|---|---|---|
| composite outcome measure | Death, subsequently transfer to ICU, relapse, need to be ventilated after 24 hours of their admission in ER | at Day 30 |
| Measure | Description | Time Frame |
|---|---|---|
| composite outcome | Death, subsequently transfer to ICU, relapse, need to be ventilated after 24 hours of their admission in ER | at Day 7 of ER admission |
| correlation between Mr proADM and patients Severity |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Nicolas Roche, MD PHD | Hotel Dieu Hospital Paris | Study Chair |
| Martin Dres, MD | Hopital Bicêtre Le Krémlin Bicêtre | Study Director |
| Pierre Hausfater, MD PHD | Pitié Salpétrière Hospital Paris | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Hôpital Lariboisière | Paris | Paris | 75010 | France | ||
| Pitié Salpétrière Hospital |
Not provided
| ID | Term |
|---|---|
| D008171 | Lung Diseases |
| ID | Term |
|---|---|
| D012140 | Respiratory Tract Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Correlation between MR proADM and patient's severity
| at Day 7 and Day 30 of ED admission |
| Paris |
| Paris |
| 75013 |
| France |